The $200
Billion Scam
By Jeff Kamen
Why the government
tries to bury the real cures.
Kathy Keeton's
successful battle against cancer is more than personal good
news--it has blown open a Washington scandal of astonishing
proportions.
She wears fitted black pants and an ivory blouse
accented by wisps of silk, which the warm wind wraps tightly
around her dancer's body. A man walking his white miniature
French poodle directly in her path cannot keep from staring, and
she has to tack around him to rendezvous with the sleek limo
waiting at the corner for her and the solidly built man who
follows a few paces back. *She is one of those graceful women you
usually see only in the pages of high-fashion magazines. The
angular bone structure, the edgy style, the controlled,
hard-bodied personal power, is all hallmarks of her thoroughbred
beauty. Such women compel us, but also keep us at a distance. You
could empathize with the guy with the dog, who for a moment
couldn't move when she appeared out of nowhere and seemed to
float straight at him. He probably missed the strange-looking
leather case hanging from her right shoulder. A slim tube runs
from the box discreetly into her clothing and then into her. It
is a self-administered pain-control unit. Whenever the pain from
the cancer she is fighting becomes too much to bear, she presses
a button and another dose of medication pushes into her
bloodstream, driving back the agony one more time. Kathy Keeton,
Vice-Chairman of General Media International and wife of
Penthouse Publisher Bob Guccione, enters the limo, curls into the
deep leather seat, and reaches with her right hand to smooth her
husband's windblown hair. He has just closed the door, ordered
the driver to head for Kennedy Airport, and asked after the
comfort of a guest who is sitting on the floor in front of them,
struggling to insert a balky cassette into a tape recorder. As
the low-tech problem is being solved, Keeton stares out the
window, watching the East Side of Manhattan pass in review. It
was six months since they were at Cannes, on the eve of the
opening of the 1995 film festival. There, suddenly, Kathy had
become ill - deeply, nauseatingly ill. At first she figured it
was food poisoning. Nothing else made much sense. Only six weeks
earlier she had passed her annual physical, including a
mammogram, with a perfect score. What would you expect from the
founder of Longevity magazine and a global advocate of
healthy living, who not only talked the talk but also danced the
steps of vigorous exercise and high-fiber diet. Nevertheless she
fell deeper into the unexplained illness, and Bob flew them home
immediately.
Within hours of landing in New York City, Kathy was seen
by her family physician, which probed, listened, and did
not like what he suspected. He did some tests, told her to come
back in a few hours, and then ordered her to see a specialist a
few blocks away. Minutes later Kathy Keeton walked into the
oncologist's office, was directed to a small cubicle, where she
removed and folded her clothes, put on a hospital gown, and
waited for the doctor to examine her and tell her what was
happening to her. In that moment of waiting Kathy began to know
in her gut that something truly awful was wrong.
"I'm sorry," she remembers her doctor saying.
"It's a very rare form of the disease. It's called galloping
breast cancer, because it starts by spreading rapidly from what
had only recently appeared to be perfectly healthy tissue. The
mammogram we took six weeks ago was not in error. The cancer
simply wasn't detectable at that time. It's the nature of this
kind of cancer that it takes off at a gallop, and metastasizes
quickly So we need to act quickly, get you started on
chemotherapy at once. We have some of the best people in the
world in this field here at Mount Sinai, and I urge you to let me
get you into their expert care. There is no time to waste. This
form of cancer is often fatal, and quickly so. Untreated, you
have six weeks to live. We really must move aggressively with the
chemo." In this circumstance most people immediately
surrender to the direction of their doctors and undergo one of
the great gambles of modern medicine. They begin a regimen of
cell-poisoning chemotherapy, hoping that the powerful drugs will
kill their tumors. Along the way the chemo usually shatters the
life of the patient with waves of horrendous nausea and pain.
Many cannot bear the suffering, and choose to drop the chemo
and be sedated until the inevitable occurs. For those who endure
the chemo the outlook is not good, statistically. Only about 20
percent of patients are cured. The rest die anyway
Kathy and her husband knew a lot about all of this, years
before it happened to her. Their magazines reported on cancer
research and controversy. For more than a decade Kathy and Bob
had published investigative stories about the work of Joseph
Gold, M.D., a former U.S. Air Force research physician and now
director of the Syracuse (New York) Cancer Research Institute.
Gold had discovered that small doses of hydrazine sulfate, a
chemical used in rocket fuel, could function as an effective
anti-cancer drug, and did so without any of the side effects of
standard chemotherapy. Gold's discovery, which first attracted
the attention and support of the cancer establishment in the
mid-1970s, just as quickly earned the enmity of the
chemotherapists who had taken over the leadership of the federal
war on cancer. If Gold's experimental drug turned out to be as
efficacious as initial studies and case reports indicated, there
would be a lot less demand for chemotherapy. Further complicating
matters, hydrazine sulfate is dirt cheap, unlike standard
cytotoxic chemotherapy agents. The price of a single dose of
chemo would buy a ten-year supply of hydrazine sulfate.
Kathy and Bob decided to hold off the Mount Sinai team, and
called in Dr. Gold to see if, after all those years of supporting
hydrazine sulfate in their magazines, the drug might work for
them.
Gold examined Kathy and recommended a course of hydrazine
sulfate. The Mount Sinai team warned Kathy that hydrazine sulfate
would be a waste of her rapidly diminishing time. Kathy and Bob
put up a united front, demanding that their doctors support Dr.
Gold's recommendations and make sure the hydrazine sulfate was
properly dispensed to her in the hospital and subsequently at
home, according to the established, published protocol. The
doctors watched disapprovingly as, taking her first hydrazine
capsule, Kathy waited and prayed.
Her diary entry for Saturday, August 11,
1995:
Joe Gold is my shepherd, I shall not
die,
He leadeth me thru green pastures.
Yea, though I walk through the valley of
the shadow of the Crab, his care and
his calls shall comfort me, and / shall
dwell in the house of Hydrazine forever
In the pursuit of this story what has been uncovered is a
skein of lies and betrayal-not by politicians or C.I.A. spooks,
but by physicians and health-care investigators, many of whose
salaries your federal taxes pay. It begins with the National
Cancer Institute, pulls in the Food and Drug Administration, and
ends up-perhaps most shockingly-with the U.S. General Accounting
Office, Congress's own investigative agency.
In the 25 years since the federal government declared war on
cancer, an estimated $200 billion has been spent by U.S.
taxpayers and private investors on research that has produced so
little bang for the buck that it makes the Pentagon's $600 toilet
seats look like bargains for every American home. The cancer
industry has become a huge jobs program for brilliant, even
highly motivated, doctors and other scientists, whose efforts are
misguided by the economic forces behind the industry. Directly
put, it's in the interests of all the fat cats in government and
private enterprise who earn their living and status from what is
largely a failed enterprise, to stick with it. That is why a drug
like hydrazine sulfate is dumped on by the cancer establishment,
instead of given legitimate support and honest evaluation.
The GAO--with its proud past of fair, impartial audits of the
performance of other federal agencies-appears to have done
something underhanded in the case of hydrazine sulfate. It has
demonstrated a level of incompetence and avoidance of controversy
that's stunningly atypical of this investigative agency and its
track record of unflinching pursuit of the truth without fear or
favor. In fact the tenor of the incompetence leads to the
inescapable conclusion that a deliberate deceptions cover-up-was
perpetrated to save other federal officials and the government
itself from a scandal of astonishing proportions.
The GAO defied logic, reason, and science to give its blessing
to what in fact has to be seen as the NCI's deliberately biased
testing of hydrazine sulfate, which falsely made the drug appear
to be without merit. What is so damaging to the GAO is that its
investigators did their fact-finding jobs well, but the
higher-ups who wrote that agency's report avoided the inescapable
conclusion that the NCI had betrayed the medical community and
cancer patients everywhere by rigging the clinical trials.
The GAO's investigators began their work by going through more
than 100 pages of documents and hours of videotape obtained by Penthouse
in pursuing this story over the preceding three years. They
confirmed many of the allegations brought to them by Penthouse.
The crucial consideration is that established medical
practice forbids the use of alcohol, tranquilizers, or sleeping
pills by patients taking hydrazine sulfate because those
"incompatible agents" not only deactivate hydrazine's
therapeutic powers but also can make the sufferers much sicker.
The GA0 investigators smoked out the truth that in its initially
published study results the NCI chose not to reveal the ingestion
of those incompatibles by the participants in its nationwide
clinical trials of hydrazine sulfate.
Under pressure from the GAO investigators, doctors who
conducted one of the NCI trials admitted in a letter to the Journal
of Clinical Oncology that virtually all of the subjects had
taken tranquilizers while receiving hydrazine sulfate.
Despite those admissions, the GAO still managed in its report
to declare that the NCI's trials "were not flawed."
That's the equivalent of describing a car as having a broken
transmission, four punctured tires, and useless brakes, but the
vehicle is nevertheless just fine, thank you, and quite capable
of carrying you safely on the interstate. In this pronouncement
the GAO participated in wrecking the hopes of millions of cancer
sufferers, dooming many to unnecessary suffering or premature and
painful death.
In the "In" baskets of the upper echelons of the GAO
there sits a direct challenge to the integrity and credibility of
that much-admired organization. It is an unanswered eight-page
letter from Dr. Gold, who as a young physician was part of the
NASA medical team that made sure Colonel John Glenn was fit for
his historic mission. For the past quarter-century Joe Gold has
been fighting to win from the American cancer establishment
acceptance of the astonishingly effective and inexpensive
anti-cancer drug that he developed. For most of those 25 years
the most influential people at the NCI and its major grantee
institutions have rejected and vilified hydrazine sulfate, which
costs less than a dollar a day and has no significant side
effects when the established protocol is properly followed.
When the NCI published its deeply flawed taxpayer-funded
national tests of the drug, making it appear ineffective, the FDA
stopped issuing "compassionate use" permissions for
physicians requesting hydrazine sulfate for their patients. That
choked off the very limited official supply of the drug,
prompting desperate patients-as well as some physicians whose own
loved ones' lives were hanging by a wire-to seek other,
unofficial lines of supply.
One respected member of the cancer establishment, medical
oncologist Lynn H. Ratner, M.D., who has a private practice in
New York, is on the faculty of the Mount Sinai School of
Medicine. He runs the cancer-education program for physicians at
Lenox Hill Hospital and has decided to go public (see sidebar at
end of article) with his own use of hydrazine sulfate.
Dr. Ratner told me in April of this year: "There are over
25 patients taking hydrazine sulfate [in our practice], 15 of
them under my direct care.... The drug has helped my patients
avert the terrible effects of cachexia [cancer-induced
starvation].... It is important to note that this drug is working
against cachexia in all 15 cases that I am personally monitoring.
"It is abundantly clear to me that hydrazine sulfate
deserves another clinical trial that would be conducted in a
double-blind fashion in good-risk candidates who are not taking
other anti-cancer drugs."
"On the important issue of incompatibility, I think Dr.
Gold is right, and the NCI needs to conduct the trials
differently. The new clinical trials I am calling for should
exclude those substances identified as incompatible, and it
should be fair and impartial, without the biases that afflicted
previous nationwide multi-institution clinical trials run by the
NCI You can't argue with the kind of success I am seeing in my
patients."
As this article was going to press Dr. Ratner told me he had
begun documenting antitumor activity in one patient receiving
only hydrazine sulfate.
If there is anyone in your life who has cancer, this article
will be very personal indeed. It has been personal for me for a
long time. It was nine years ago that I first learned of
hydrazine sulfate. It was prescribed for my mother as a
last-ditch treatment. She had nothing to lose; she had smoked her
way into lung cancer, which ultimately spread to her brain and
throughout her body. Erna Kamen was only 64 and an athlete, but
none of that helped much. The surgeons and radiation specialists
had done everything they could. At one point, to get even more
radiation therapy than is generally allowed, she signed a release
authorizing the doctors to give her yet another course of
radiation. The family joke was that one more treatment and she
would glow in the dark. Despite our hopes and prayers, the cancer
continued its relent less assault, and further treatment was
deemed to be useless.
As the widespread tumors disrupted her system's capacity to
process nutrients, her body shrank. My mom lost massive amounts
of weight, along with her mental acuity. She virtually
disappeared into her bedclothes. After yet another race to the
hospital emergency room, I was told by her oncologist that she
had only days to live, and that we should "take her home and
make her as comfortable as possible" until she died.
The next day, at the direction of the oncologist, she started
hydrazine sulfate. She managed with some water to swallow one
capsule. We didn't have much hope that it would do anything for
her. After all, only hours earlier the NCI's 1-(800)-4-CANCER
public-information line had told us that hydrazine sulfate was
worthless.
I needed to escape from the mounting emotional pain. So I
pulled on shorts and shoes for an hour's hard run, determined to
numb my brain by pounding the concrete drawbridges and blacktop
that lead to downtown Sarasota, Florida. Finally exhausted, I
returned, showered, and fell into a deep, troubled sleep. Next
thing I knew, my mother's nurse was shaking me awake.
"Is she
gone?" I asked
The nurse laughed.
"Gone? Are you kidding? I don't believe it. She's trying
to sit up in bed, and she wants you to get up there. Listen!
That's her yelling for you to join her for breakfast. She
actually wants to eat! "Hydrazine sulfate was my mom's
ticket to renewed life, and it brought her back for about four
months, much of which she enjoyed. Although she back 23 pounds,
hydrazine sulfate didn't get a chance to do everything it could
for her. She died after her medical team had made a major error
in judgment: Her medication was switched, and she was taken off
hydrazine sulfate.
Kathy Keeton sits at her computer, answering anxious e-mail
queries about the drug. Much of her legendary energy has
returned, which she now uses tirelessly to help other patients
with cancer. She has hired a staff and provided it with space in
the Penthouse offices, from which answers are sent to the
thousands of inquiries received by Penthouse each week, as
well as information on how to obtain hydrazine sulfate. Kathy has
gone public with her experience. She has been in print in dozens
of newspapers, on television and radio in the US and Europe. All
of which has thrown a spotlight on peer-reviewed medical
literature affirming the drugs safety and efficacy at all stages
of cancer.
But despite her advocacy of hydrazine sulfate, Kathy is
outspoken in her gratitude to the staff at Mount Sinai for
helping her fight for her life. "The doctors are really
wonderful, and I can't say enough in praise of the warm and
supportive nurses who did everything in their power for me,"
she says with passion. "It's not their fault that the
medical establishment they're part of prevents them from
appreciating hydrazine. It's the NCI that's the real villain
here."
Almost a decade earlier thousands of people called in to TV
stations, seeking information and help, in response to the seven
times I appeared on Independent Network News, 1988 to 1990,
reporting on the hydrazine-sulfate story and-on four of those
broadcasts-the story of my mother.
Feeling the mounting pressure from my broadcasts and from Penthouse's
investigations, as well as ten years of double-blind positive
clinical studies reported by UCLA's Harbor Hospital, the National
Cancer Institute finally went forward. Its long-awaited
multi-institutional Phase III clinical trials of hydrazine
sulfate got under way in 1989 and 1990. I had hoped that my
report would in part lead to the rescue of hundreds of thousands
of cancer patients who would soon gain access to this low cost,
uniquely effective medication. But that sweet dream would become
a nightmare.
By April of 1993 1 was writing in Penthouse that the
NCI had prejudiced its nationwide testing of hydrazine sulfate by
including in its study an unspecified number of cancer patients
who had not been kept from using alcohol, tranquilizers, or
barbiturates. This was incomprehensible.
Even the FDA itself had long warned physicians administering
the drug to make sure patients did not consume alcohol,
tranquilizers, or sleeping pills. (For almost ten years the FDA
had made hydrazine sulfate available to doctors on a
"Compassionate Use" basis.) I brought all this
information plus supporting documentation (more than 100 pages)
to the House of Representatives subcommittee with oversight
responsibility for the NCI.
In Penthouse for July 1994 I wrote about the Russian
oncology-research community's illuminating experience with
hydrazine sulfate. There, it has been brought to bear against a
broad array of "incurable" cases of lung, lymphatic,
and 30 other types of cancer, with surprisingly good results, for
what is now almost a quarter century. One of the more startling
findings by the Russians is hydrazine sulfate's effectiveness
against cancerous and non-cancerous tumors of the brain.
Non-cancerous brain tumors are fearsome because they expand until
they crowd out the brain, causing blindness, paralysis, and
death. The Russians report that hydrazine-sulfate treatment
results in a 45-percent response rate for cancerous brain tumors
and a 65-percent response rate for non-cancerous brain tumors.
The Russian doctors strictly forbid the use of alcohol,
barbiturates, or tranquilizers by patients on the treatment. As
one prominent Russian researcher (and former NCI consultant),
Michael Gershanovich, M.D., told me: "Why would you want to
give these things to patients receiving the hydrazine sulfate?
The hydrazine sulfate would not work, and that would be
wrong."
At the Petrov Research Institute of oncology in St. Petersburg
I heard a great deal about the Russian doctors' fear of offending
America's all-powerful, grant-giving NCI -an institution with
which the Petrov had enjoyed 17 years of collegial relations via
the Joint U.S. - USSR Cancer Agreement.
But in the United States the NCI - sponsored researchers chose
not to follow the Russian lead. Patients in the NCI -approved
study protocols were permitted to drink alcohol and pop
tranquilizers and sleeping pills. No fewer than 94 percent of
those in one of the trials are known to have consumed one or more
tranquilizers. Which means that only six percent of the
subjects-16 of them, in this case-had any realistic chance of
benefiting from the hydrazine sulfate. Want to bet that none of
the 266 patients in this particular study was told in the
required "informed consent statements" that the odds of
getting any benefit at all had been reduced to about zero even
before he or she swallowed the first capsule? Or been told that
the consumption of alcohol, barbiturates, or tranquilizers could
not only negate the therapeutic effect of hydrazine sulfate but
cause, as the profession gently puts it, "morbidity and
mortality"-sickness arid death?
The 16 patients whose charts do not show the presence of any
incompatibles totaled roughly one-quarter the number of people in
a previous clinical trial at Harbor-UCLA that, through its
positive outcome, had inspired much of my reporting. The NCI
initially dismissed those results because the number of patients
involved was too small, they said, to be statistically
significant.
In 1994, a year before the great love of his life would come
down with breast cancer, Bob Guccione was a guest along with Dr.
Joseph Gold on a talk-radio program I hosted on WWRC in
Washington, D.C. On the air Guccione laid out the sorry history
of the NCI's bitter and determined resistance to giving hydrazine
sulfate a fair test, and Gold explained how the drug works. The
stations phone lines were quickly besieged by impassioned
listeners who wanted to know what they could do to help. I
suggested that they phone and fax Edolphus Towns (DL-N.Y.), then
chairman of the House Intergovernmental Relations Subcommittee,
which has the authority to investigate the NCI. Within minutes
the congressman's staff called us, demanding that we stop giving
out the number, that the program's listeners were "making it
impossible for us to get our jobs done." We politely
declined to call off our listeners. A second call came from a
senior aide to the chairman, who promised to get his boss to read
the massive documentation I had submitted to the subcommittee ...
a year before the broadcast.
Within a week the chairman ordered the GAO to conduct an
investigation into the matters raised by Penthouse. When
the GAO's investigators called upon senior officials of the NCI
they ran into anger and resentment. At one point,informed sources
say, there was considerable shouting and screaming, and a sense
of NCI gloom over the possible outcome of the congressional
investigation--a concern over what the costs might be to the
powerful men and women who had waged war against the drug and its
developer, and therefore against cancer patients. But the NCI
brass shouldn't have lost much sleep. The damage, as it turned
out, would be very small indeed, and quite contained. No heads
would roll; no blame would be fixed. Business-as-usual would
prevail.
This is how it worked: The GAO slapped the wrists of the NCI
for sloppy, incomplete record keeping of the drugs other than
hydrazine sulfate that were taken by the patients in the clinical
trials. As a result, NCI's team leaders, as indicated, admitted
in a letter to the Journal of Clinical Oncology what they
hadn't bothered to disclose in their original report to the
medical community-that 94 percent of the patients in one study
had received one or more tranquilizers. But if you didn't already
know that tranquilizers (and barbiturates and alcohol) were
incompatible with hydrazine sulfate, the NCI letter wouldn't have
helped you to learn that. It simply confessed to not having fully
reported on other drugs consumed by patients in the study. The
NCI has always rejected the fact that some substances are
incompatible with, and therefore deactivate, hydrazine sulfate,
and that the mix can be extremely dangerous. Thus the NCI letter
didn't tell the truth, didn't warn that mixing the incompatibles
with the hydrazine sulfate was a time bomb.
Then in late 1995 came the official GAO report. It upheld the
NCI's testing methods in this case, making the GAO's long awaited
probe of the whole affair a veritable whitewash.
The GAO's report is a stunning defeat for millions of cancer
patients and their families in the United States and around the
world. To affirm the NCI's destructive conclusion--to say that
the NCI's hydrazine-sulfate studies "were riot
flawed"--the GAO had to buy into the deceptive
pronouncements and statistics that are at the core of the NCI's
case.
When Congress ordered the GAO probe it was believed that the
GAO would conduct an independent audit of the NCI's
methodology--but hat did not happen. Instead, after an
"internal review," the GAO accepted the NCI's own
"retrospective analyses."
Penthouse hired independent medical-statistics
consultant Richard Wilkins, a former senior biostatistician at a
major pharmaceutical manufacturer. He was asked to evaluate the
NCI's retrospective analyses." Because of my long and
emotional investment in the case, I waited with some apprehension
for Wilkins's report. What if it were I who was biased in my
reporting? What if all those great results in Russia and America
had been flukes?
I shouldn't have worried. My copy of Wilkins's conclusions
came with a cover letter saying, "You are to be
congratulated for bringing the important, indeed truly
scandalous, hydrazine sulfate story to the attention of the
American people. The enclosed should provide more ammunition for
it."
The hostility toward hydrazine sulfate at the NCI is bone
marrow deep. The NCI's longtime former director, Vincent T. De
Vita, Jr., M.D., now head of the Yale University Cancer Center,
had long attacked Dr. Gold and belittled his discovery. He told
the Washington Post, " it's a ho-hum drug," and
the ABC News program "20/20," "We throw away
better drugs than hydrazine sulfate." A renowned pioneering
chemotherapist and a master at the politics of cancer, De Vita is
an icon in the cancer establishment, with friendships among the
powerful in almost every corner of American and international
life. For more than a decade his word on anything having to do
with cancer rolled down like thunder across the worldwide medical
landscape. So it should not have come as a complete surprise that
the GAO's deck would be stacked against a full and fair
assessment of the NCI's hydrazine-sulfate trials. To come up with
anything else would have reflected terribly on the NCI power
structure, past and present.
Listen in as Mark Nadel, assistant director of the General
Accounting Office, attempts, in a telephone interview with me, to
justify the method and administration of the NCI's clinical
trials of hydrazine sulfate: "The reason [the use of
tranquilizers) was incompatible, which threw us at first, was
that it would heighten the sedative effect [of hydrazine
sulfate]. In any case, in the admittedly small number of patients
in the trials who did not receive the incompatibles, there was no
(positive) effect seen of hydrazine sulfate and the issue of
statistical significance shouldn't blind one to the fact that no
(positive) effect was seen.
Nadel must have assumed that I wasn't paying attention, and
that you, the reader, cannot think. Why do major clinical trials
routinely embrace hundreds of patients and not just a few dozen?
Because statistical significance is at the very core of measuring
the success or failure of any experimental medication. For the
sake of his report's credibility, Nadel wants us to ignore the
importance of statistics.
Here's Dr. Gold on that question: "It is impossible to
state that no effect was seen, because there weren't enough
patients who did not receive the incompatibles to document
whether an effect was seen. Mr. Nadel's insistence that the issue
of statistical significance I shouldn't blind one' is stunning,
since it is only statistical significance which can confirm any
effect in a clinical trial. It is the basis of all clinical
trials, and he knows it.
"The fact that hydrazine sulfate heightens the sedative
effect of the incompatibles is only a secondary consideration of
incompatibility. The primary consideration, which is demonstrated
by both published and unpublished studies which were made
available to the NCI before the commencement of any of their
clinical trials, is that the combination of hydrazine sulfate and
tranquilizers nullifies the therapeutic effect of hydrazine
sulfate and causes vastly increased risk of additional illness
and even death in test subjects.
"Additionally, prior to the commencement of the NCI's
clinical trials of this drug I alerted NCI that hydrazine sulfate
is a member of the class of drugs called MAO inhibitors. As such,
a patient who also is taking tranquilizers, barbiturates, beer,
wine, or hard liquor cannot use it. It also cannot be used by
patients who are permitted to eat raisins, yogurt, and a list of
other foods containing tyramines (amino-acid derivatives). The
NCI made no attempt to monitor any of these things in its
studies, which can also have the effect of turning off hydrazine
sulfate's capacity to stop cancer-induced starvation and shrink
the tumors themselves.
"Since hydrazine sulfate is an MAO inhibitor, and since
MAO inhibitors and tranquilizers are recognized as incompatible,
then the NCI studies are by definition intrinsically flawed. The
use of incompatible agents constitutes negative-bias factors in a
study design, and the effect of negative-bias factors is to
produce a negative outcome."
Kathy Keeton, whose silken hair, lustrous complexion, and
flashing eyes do not look remotely like those of a patient with
end-stage breast cancer, gives instructions to one of her
assistants. It is spring 1997. She no longer wears the strange
leather case that delivers pain medication. Kathy is full of
life. Her words flow softly, with the clipped lilt of her native
South Africa. She speaks of the information she has disseminated
about hydrazine sulfate to cancer patients and their families all
over the world. She speaks of the growing number of physicians
prescribing this drug as a result of this information. She speaks
of the class-action lawsuit her husband is considering launching
against the NCI on behalf of all those patients who were cruelly
given hydrazine sulfate without clear instructions to avoid
alcohol, antidepressants, and/or sleeping pills. Kathy Keeton is
a woman with a mission. She feels she has been literally
"touched by an angel," and is now dedicated to giving
back by helping those in need.
This reporter has turned over to Congress the Wilkins report,
which strips bare the NCI's "retrospective analyses,"
and Penthouse's and my findings on the GAO's cover-up of
the NCI's assault on hydrazine sulfate. You can help by writing,
faxing, or calling your representatives in the House and Senate.
Enclose a copy of this article; urge them to hold public hearings
on this cover-up and to demand an impartial, properly
administered large-scale clinical trial of hydrazine sulfate.
Every cancer patient on this planet should have the same
chance that saved Kathy Keeton.
Home
Contents
Grandma's Herbs Products
Miracle Products
Roex Products
Shipping Policies
* These statements have not been
evaluated by the Food and Drug Administration. These products are not intended to
diagnose, treat, cure, or prevent any disease. This information is nutritional in nature
and should not be construed as medical advice. This notice is required by the Federal
Food, Drug and Cosmetic Act.
Copyright © 2010 Mindbodyhealth All rights reserved
Last modified:
July 22, 2011
